JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to r...
Main Authors: | Andrew T. Kuykendall, Rami S. Komrokji |
---|---|
Format: | Article |
Language: | English |
Published: |
Innovative Healthcare Institute
2021-08-01
|
Series: | Journal of Immunotherapy and Precision Oncology |
Subjects: | |
Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-20-36 |
Similar Items
-
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2020-08-01) -
Recent progress of JAK inhibitors for hematological disorders
by: Keita Kirito
Published: (2023-07-01) -
Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01) -
Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
by: Naveen Pemmaraju, et al.
Published: (2022-11-01) -
Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
by: Ayesha Gul, et al.
Published: (2022-06-01)